Setting a new bar? Zealand touts 'placebo-like tolerability' for Roche-partnered weight loss drug

Researchers at Zealand Pharma and Roche are developing a new medication that could change how we treat obesity. In a recent clinical trial, patients taking this new drug lost an average of up to 10.7 percent of their body weight over a period of 42 weeks. The treatment belongs to a class of medications called amylin analogs. Amylin is a hormone that naturally helps regulate feelings of fullness, and an analog is simply a synthetic version designed to mimic those natural effects in the body.

What makes this experimental treatment stand out is not just the impressive weight reduction. The researchers reported that patients experienced incredibly mild side effects while taking the medication. The safety profile was so favorable that the companies described the treatment as having tolerability similar to a placebo, which is an inactive dummy pill. This is a major achievement for obesity treatments, as many existing options can cause uncomfortable digestive issues.